ReXPOsing a weakness in TP53-mutant MDS and AML
- PMID: 41165696
- DOI: 10.1182/blood.2025030746
ReXPOsing a weakness in TP53-mutant MDS and AML
Comment on
-
XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies.Blood. 2025 Oct 30;146(18):2244-2258. doi: 10.1182/blood.2025028803. Blood. 2025. PMID: 40737597
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
